Aptose Biosciences Inc Total Liabilities
Aptose Biosciences Inc total liabilities. Based on the latest financial reports, Aptose Biosciences Inc (APS) has total liabilities worth CA$25.79 Million CAD (≈ $18.66 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Aptose Biosciences Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Aptose Biosciences Inc (1996–2024)
Total liabilities of Aptose Biosciences Inc from 1996 to 2024. This chart illustrates how Aptose Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data.
Aptose Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Aptose Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Northern Shield Resources Inc.
V:NRN
|
Canada | CA$453.58K |
|
Triton Minerals Ltd
AU:TON
|
Australia | AU$12.38 Million |
|
AUX Resources Corporation
V:AUX
|
Canada | CA$225.92K |
|
PDZ Holdings Bhd
KLSE:6254
|
Malaysia | RM9.13 Million |
|
Ronin Resources Ltd
AU:RON
|
Australia | AU$121.73K |
|
Marston’s PLC
LSE:MARS
|
UK | GBX1.53 Billion |
|
Blue Ocean Acquisition Corp
NASDAQ:BOCN
|
USA | $16.05 Million |
|
Jackpot Digital Inc
V:JJ
|
Canada | CA$13.09 Million |
Liability Composition Analysis (1996–2024)
This chart breaks down Aptose Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see APS total assets.
Liquidity & Leverage Metrics
Aptose Biosciences Inc Total Liabilities Ratios Explained
Aptose Biosciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aptose Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aptose Biosciences Inc (1996–2024)
The table below shows the annual total liabilities of Aptose Biosciences Inc from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$14.67 Million ≈ $10.61 Million |
-7.68% |
| 2023-12-31 | CA$15.89 Million ≈ $11.49 Million |
+19.60% |
| 2022-12-31 | CA$13.29 Million ≈ $9.61 Million |
+60.28% |
| 2021-12-31 | CA$8.29 Million ≈ $6.00 Million |
+12.82% |
| 2020-12-31 | CA$7.35 Million ≈ $5.31 Million |
+12.17% |
| 2019-12-31 | CA$6.55 Million ≈ $4.74 Million |
+134.85% |
| 2018-12-31 | CA$2.79 Million ≈ $2.02 Million |
+58.02% |
| 2017-12-31 | CA$1.76 Million ≈ $1.28 Million |
+33.92% |
| 2016-12-31 | CA$1.32 Million ≈ $953.42K |
-22.56% |
| 2015-12-31 | CA$1.70 Million ≈ $1.23 Million |
-15.33% |
| 2014-12-31 | CA$2.01 Million ≈ $1.45 Million |
+14.09% |
| 2013-12-31 | CA$1.76 Million ≈ $1.27 Million |
-32.31% |
| 2012-12-31 | CA$2.60 Million ≈ $1.88 Million |
+119.38% |
| 2011-12-31 | CA$1.19 Million ≈ $858.27K |
-56.00% |
| 2010-12-31 | CA$2.70 Million ≈ $1.95 Million |
-81.49% |
| 2009-12-31 | CA$14.57 Million ≈ $10.54 Million |
-6.31% |
| 2008-12-31 | CA$15.55 Million ≈ $11.25 Million |
+13.01% |
| 2007-12-31 | CA$13.76 Million ≈ $9.95 Million |
+8.07% |
| 2006-12-31 | CA$12.73 Million ≈ $9.21 Million |
+11.71% |
| 2005-12-31 | CA$11.40 Million ≈ $8.24 Million |
0.00% |
| 2004-12-31 | CA$11.40 Million ≈ $8.24 Million |
+166.57% |
| 2003-12-31 | CA$4.28 Million ≈ $3.09 Million |
+90.40% |
| 2002-12-31 | CA$2.25 Million ≈ $1.62 Million |
0.00% |
| 2001-12-31 | CA$2.25 Million ≈ $1.62 Million |
-41.13% |
| 2000-12-31 | CA$3.81 Million ≈ $2.76 Million |
+58.39% |
| 1999-12-31 | CA$2.41 Million ≈ $1.74 Million |
+173.12% |
| 1998-12-31 | CA$881.66K ≈ $637.78K |
+16.75% |
| 1997-12-31 | CA$755.18K ≈ $546.29K |
-5.38% |
| 1996-12-31 | CA$798.14K ≈ $577.36K |
-- |
About Aptose Biosciences Inc
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloi… Read more